Taysha gene therapies provides update on deprioritized pipeline programs

Dallas, feb. 15, 2024 (globe newswire) -- taysha gene therapies, inc. (nasdaq: tsha) (“taysha” or “the company”), a clinical-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns), today provided an update on its deprioritized pipeline programs as part of an ongoing effort to help support their further potential development.
TSHA Ratings Summary
TSHA Quant Ranking